With core competencies in discovery, target biology and pre-clinical drug development, ImmuNext is organized around development of immunomodulatory compounds designed to modulate the immune system to treat cancer and autoimmune diseases. Negative checkpoint regulators are changing the way cancer is treated. ImmuNext's lead product, anti-VISTA, is partnered with Janssen for the treatment of cancer. A second product, VISTA agonists, is partnered with Hoffmann-La Roche for the treatment of autoimmune diseases. Other programs include a CD40 agonist for neoantigen cancer vaccines and a novel immuno-metabolic target, in each case establishing new classes of compounds. ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. The immunoregulatory molecule, CD40L, is critical to the progression of a wide spectrum of autoimmune diseases. Antibodies that block the function of CD40L have proven in pre-clinical models of autoimmunity to be effective agents in treating disease. The development of anti-CD40L for the treatment of autoimmune diseases offers a unique opportunity to silence disease progression and offer long-term remission.
